Jaydess (Levonorgestrel)

Levonorgestrel released from the device acts locally on the uterine lining, suppressing endometrial growth and thickening cervical mucus. These actions together hinder sperm movement, may prevent ovulation, and create an environment that is unfavorable for implantation, thereby reducing the chance of pregnancy.

The dose and duration of Jaydess are predetermined by the manufacturer and selected by the prescribing clinician based on the patient’s contraceptive needs. The prescriber decides whether the device is appropriate; patients should not alter the device or its dosing regimen.

Jaydess is not intended for use during an existing pregnancy. If pregnancy occurs while the device is in place, it should be removed promptly. Limited data suggest it is compatible with breastfeeding, but clinicians usually assess individual risk‑benefit before continuation.

To order Jaydess, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Jaydess offers continuous low‑dose levonorgestrel release, providing up to three years of protection without daily dosing, unlike oral contraceptives. Compared with copper IUDs, it may cause less menstrual bleeding but can lead to hormonal side effects. Its efficacy is comparable to other hormonal IUS devices such as Mirena, while offering a slightly shorter approved duration.

Jaydess should be stored at ambient temperature, below 25 °C, in its original sealed packaging. It must be protected from moisture, direct sunlight, and extreme temperatures. Healthcare providers should handle the device with clean, dry gloves during insertion to maintain sterility.

Jaydess is inserted by a trained healthcare professional into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting after confirming the patient is not pregnant and that the uterine cavity is suitable. Once placed, the device remains in situ for up to three years unless removal is required.

Serious risks include uterine perforation during insertion, device expulsion, pelvic inflammatory disease or infection, and the rare possibility of ectopic pregnancy if contraceptive failure occurs. Patients should be instructed to seek immediate medical attention for severe abdominal pain, abnormal bleeding, or signs of infection.

Jaydess is contraindicated in women who are currently pregnant, have unexplained vaginal bleeding, known or suspected uterine or breast cancer, active pelvic infection, severe liver disease, or anatomical uterine abnormalities that would impede proper placement. Individuals with a history of thromboembolic disorders should also discuss alternatives with their clinician.